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Background: Diagnostic biomarkers for heart failure (HF) such as the natriuretic peptides (NPs) are widely used
but have limitations. Innovative biomarkers could provide improved diagnostic performance.
Methods:We launched a prospective case–control proteomic study and investigated for polypeptides speciﬁc to
HF through a capillary electrophoresis-mass spectrometry (CE-MS) proteomic analysis. The putative biomarker
was identiﬁed by Orbitrap liquid chromatography-MS, validated by western blot, then by ELISA using plasmas
from multicentric international cohorts. A rat model of HF was tested for biomarker expression levels.
Results:We identiﬁed insulin like growth factor binding protein 2 (IGFBP2) as a new diagnostic biomarker for HF
with a high sensitivity and speciﬁcity (AUC= 0.93; 95% CI, 0.89-0.96; p b 0.0001) in the local cohort and IGFBP2
levels provided an AUC of 0.943 (95% CI, 0.860-1.026)which gave a 87 % sensitivity in AHF and 90 % speciﬁcity at
the cut off value previously determined in the discovery cohort, i.e. 556 ng/ml. ROC curve analysis of IGFBP2 and
NTproBNP showed anAUC of 0.784 (95% CI, 0.744-0.820) for IGFBP2 and a signiﬁcantly higher AUC of 0.927 (95%
CI, 0.900-0.949) for NT-proBNP, p b 0.0001 in a Dutch cohort. In this cohort, the optimal cut off value for IGFBP2
gave a sensibility of 71% (95% CI, 66–76) and a speciﬁcity of 75% (95% CI, 65–83).
Conclusion: IGFBP2 is a new biomarker to diagnose HF which could be used to provide additional information to
the NPs. Animals models will help in the evaluation of the putative IGFBP2 regulated mechanisms in HF.
Clinical Trial Registration: ClinicalTrials.gov NCT01024049.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Exposure of the population to the growing incidence of cardiovascu-
lar risk factors such as obesity, diabetes or aging increases the preva-
lence of heart failure (HF)[1]. In these populations, diagnosis of HF
remains often difﬁcult. Several HF biomarkers, detected mainly in
blood have already been validated [2]. The natriuretic peptides family
(NPs) has become of major importance at Emergency Departmenthe reliability and freedom from
ion.
land Ltd. This is an open access articl(ED) for the differential diagnosis of acute dyspnea and for stratiﬁcation
of patients with HF. Amongst these, the B-type Natriuretic Peptide
(BNP) and its cleavage equivalent N-terminal pro-B-type natriuretic
peptide (NT-ProBNP) are commonly used [2]. However, because of the
NPs grey zone values, which do not allow to rule-in nor -out for diagno-
sis of 25 % to 35 % of dyspneic patients, additional time consuming and
expensive examination as TTE or cardiac MRI are required [3–6].
Furthermore, it is well established that the time to establish an accurate
diagnosis,mandatory to start an effective treatment, is amajor prognos-
tic factor in HF patients [7]. Despite the usefulness of NPs, there is still a
need for additional biomarkers that could complement and give more
accuracy to the existing ones. NPs have been measured in urine and
revealed a similar discriminating power in plasma and urine for hearte under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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has not yet been widely investigated for HF, could be a potential reser-
voir for new biomarkers.
In this study by usingMass spectrometry-based proteomics of urine,
we report the discovery IGFBP2 as a new candidate diagnosticmarker of
HF. Using a sensitive ELISA assay, discriminating capacities of IGFBP2 to-
wards HF were determined in plasma samples from a local discovery-
validation cohort and two multicentric international cohorts. Finally, a
rat model of HF was tested for IGFBP2 gene expression levels.2. Material and methods
2.1. Patients
Three independent cohorts were used in this study. The discovery
and the ﬁrst local validation cohorts were constituted with 336 patients
(224 controls vs 112 HF cases) selected from the IBLOMAVED cohort
[10] who were recruited in the cardiology and pulmology department
at the University Hospital Toulouse, France (Fig. 1A) using simple ran-
dom sampling. To focus on speciﬁc biomarkers of heart failure, without
prejudice to etiology or severity of heart failure, theHF case group of the
discovery and validation cohorts was constituted of patients suffering
from chronic heart failure (CHF) or acute heart failure (AHF). CHF pa-
tients had known stable HF with N 3 months without any decompensa-
tion episodes, irrespective of clinical severity (stage I to IV of NYHA
classiﬁcation) and etiology. Diagnosis of heart failure had been formally
established by a cardiologist from clinical observations, heart disease
follow-up, transthoracic echocardiography (TTE) for all patients and
BNP monitoring. These patients were included during their regular
scheduled visit at the hospital. AHF patients were recruited similarly
by a senior cardiologist, irrespective of clinical presentation (left, right,
mixed, low ﬂow-cardiogenic shock). Control group of the discovery
and the validation cohorts were constituted of non cardiac dyspnea
patients (NCD) patients and patients with cardiovascular risk factors
(CRF). For all subjects all clinical data were recorded by chart review.
Patients with renal dialysis or transplant (stage 5D and 5 T) were
excluded. CRF patients were recruited during their scheduled visit at
the of cardiovascular risks prevention unitwithin the cardiology depart-
ment. Inclusion in this group required the exclusion of all patients
with a history, clinical signs, biological, or TTE evidence of heart failure
(systolic or diastolic dysfunction). Finally, 224 control caseswere select-
ed with a simple random sample of 179 CRF and 45 NCD; 112 HF cases
were selected of a simple random sample of 67 CHF and of 45 AHF
(Fig. 1A). The research protocol was registered in a clinical database
(IBLOMAVED, ClinicalTrials.gov NCT01024049) conforms to the ethical
guidelines of the 1975 Declaration of Helsinki. The protocol was
approved by the institution’s human research (COSSEC) and regionalDiscovery cohort
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Fig. 1. Flow-chartethics committee (Comité de Protection des Personnes (CPP) # DC
2008–452). Written informed consent was obtained from all partici-
pants and/or their legally authorized representatives.
The second external validation cohort of 40 patients was constituted
at the Lariboisière University Hospital Emergency Department (Paris,
France) with the simple random selection of 10 NCD patients character-
ized by a BNP b 20 pg/ml as control patient and 30 AHF patients as heart
failure cases patients, diagnosed by a cardiologist (Fig. 1B).
The second external validation cohort included 90 NCD and 361 AHF
patients recruited between June 2007 andOctober 2009,whopresented
to the ED of the Maastricht University Medical Center (Maastricht,
Netherlands). AHF patients were diagnosed by a senior cardiologist
(Fig. 1C).
2.2. Biological samples
Peripheral venous blood from the three cohorts subjects was collect-
ed into EDTA tubes. After centrifugation at 1500 g at 4 °C for 10 min,
plasma was separated, aliquoted and stored at−80 °C until assayed.
Subjects from the local discovery cohort also provided a morning
urine sample, and 20 ml was collected into polypropylene collection
pot, aliquoted and stored at−80 °C (Fig. 1A).
2.3. Analytical methods
2.3.1. Sample preparation and capillary electrophoresis coupled to mass
spectrometry (CE-MS) analysis.
From the local cohort, we randomly chose 25 HF patients to consti-
tute the cases subset and 25 CRF patients to constitute the controls sub-
set. Urines from these 50 subjects were used for CE-MS proteomic
analysis; details on urine samples preparation and on the CE-MS
methodhave been providedpreviously [11,12].Mass spectrawere proc-
essed using MosaiquesVisu software (Mosaiques, Hannover, Germany)
(Fig. 1A).
2.3.2. Statistical methods and identiﬁcation of biomarkers
In the discovery phase, we compared the natural logarithm-
transformed signal amplitude of the CE-MS urinary polypeptide proﬁle
between HF and controls patients using the Wilcoxon rank sum test.
Statistical adjustment for multiple testing was performed by applying
Benjamini-Hochberg correction.
Unless otherwise speciﬁed, continuous variables are presented as
means (±SD) categorical variables as percentages. For continuous
variables, a Student’s t-test or Mann–Whitney rank sum test when
normality test failed or for categorical variables a chi square test
was used to determine their statistical differences between groups.
To assess discriminateing power of the biomarker, Receiver OperatingAHF
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of the study.
7M. Berry et al. / IJC Metabolic & Endocrine 6 (2015) 5–12Characteristic (ROC) curve were used and the area under curve (AUCs)
comparisons were performed using themethod of DeLong [13]. Contin-
uous net reclassiﬁcation improvement (NRI) applied to case–control
studies [14] was used to evaluate differences between models with a
bootstrap (n = 1000) to obtain standard error estimates. Statistical
analyses were performed using R computation language (http://www.
R-project.org) with “nricens” package version 1.2 for NRI computing
(http://www.cranr.-project.org) and Medcalc software (Medcalc, ver-
sion 11.6.0.0, Medcalc software bva, Belgium).
2.4. Sequencing
The urine samples were analysed as described [15]. For further vali-
dation of obtained peptide identiﬁcations, the strict correlation between
peptide charge at the working pH of 2 and CE-migration time was uti-
lized to minimize false-positive identiﬁcation rates [15].
2.4.1. Rats HF model and transthoracic echocardiography
The investigation conformed to the National Institutes of Health
Guide for Care and Use of Laboratory Animals was allowed by the
Inserm Animal Ethics Committee. The study, using myocardial infarc-
tion in 2 month old Sprague–Dawley rats (Janvier) by coronary artery
ligation, was approved by the Local Animal Ethics Committee (# MP/Table 1
The discovery-validation cohort demographic and clinical characteristics. CRF, cardiovascular ri
AHF, acute decompensated heart failure patients. P values of the comparison tests between CRF
versus HF (CHF + AHF) cases.
CRF
(n = 179)
CHF
(n = 67)
P
Age, years 55 ± 11 63 ± 13 b
Sex, Male, % (M/F) 61 (109/70) 67 (45/22) 0
BMI 27.4 ± 4.5 25.2 ± 4.3 0
Cardiovascular risk factors
Hypertensive, % (n) 38 (68) 39 (26) 1
Diabetes, % (n) 12 (21) 31 (21) b
Dyslipedemia, % (n) 81 (145) 58 (39) b
Obesity, % (n) 31(55) 14 (9) 0
Smoking, % (n) 12 (21) 17 (11) 0
Cardiovascular history
Coronaropathy artery disease, % (n) 3 (5) 50 (33) b
Medication
ACE inhibitor, % (n) 8 (14) 58 (39) b
ARAII, % (n) 14 (25) 10 (7) 0
Beta-blocker, % (n) 12 (21) 68 (46) b
Diuretic, % (n) 10 (18) 76 (51) b
Vitamin K antagonist, % (n) 0 (0) 46 (31) b
Antiplatelet agent, % (n) 10 (18) 56 (38) b
Statine, % (n) 37 (66) 58 (39) b
Admission labs
BNP, pg/ml 26 [22–42] 446 [307–637] b
Creatinine clairance, ml/min 92 [86–104] 56 [48–68] b
C reactive protein, mg/l 1.9 [1.5-2.2] 11.4 [7.0-15.3] b
Na+, mM 140 ± 2 138 ± 3 b
ALT, U/ml 31 [29–38] 31 [28–40] 0
Admission vitals
Mean Blood Pressure, mmHg 99 ± 11 84 ± 12 b
Heart rate, Bpm 67 [64–69] 80 [75–85] b
Echocardiography
LVEF, % 70 ± 9 35 ± 13 b
LVEF b 40%, % (n) 0 (0) 64 (43) b
Heart failure etiology
Hypertensive HCM, % (n) - 10 (7) -
Hereditary HCM, % (n) - 9 (6) -
Valvular heart disease, % (n) - 20 (13) -
Dilated cardiomyopathy, % (n) - 23 (15) -
Toxic cardiomyopathy, % (n) - 10 (7) -03/03/01/12). TTE analyses were performed using the Vivid 7 (GE
Medical System) as already performed [16].
2.5. Immune methods
Western blots were performed using rabbit monoclonal anti-human
IGFBP2 antibody (Clinisciences, Nanterre, France). IGFBP2 enzyme-
linked immunosorbent assay (R&D Systems, Inc., Minneapolis, MN,
USA) was used as per the manufacturer’s speciﬁcations.
2.5.1. mRNA extractions, reverse transcription (RT) and Realtime quan-
titative PCR (qPCR)
mRNA extractions and RT-qPCR was performed as already de-
scribed [16] using rIGFBP2F1 5‘-TGGCCTGTACAACCTCAAACAGTG-3’
and rIGFBP2R1 5’-TCGTTGTAGAAGAGATGGCACTCG-3' primers as
already performed [17].
3. Results
3.1. Discovery study
Demographic and clinical data of the local cohort are presented in
Table 1. HF cases (CHF + AHF) were older than control (CRF + NCD)sk factors patients; CHF, chronic heart failure patients; NCD, non-cardiac dyspnea patients;
and CHF or NCD and AHF; Pa value of the comparison test between control (CRF + NCD)
NCD
(n = 45)
AHF
(n = 45)
P Pa
0.001 66 ± 16 74 ± 14 0.023 b0.001
.589 47 (21/24) 45 (20/25) 1.000 0.901
.054 25.0 ± 5.9 27.1 ± 6.7 0.141 0.474
.000 51 (23) 75 (34) 0.029 0.402
0.001 20 (9) 29 (13) 0.425 b0.001
0.001 36 (16) 58 (26) 0.057 0.015
.010 16 (7) 24 (11) 0.430 0.066
.718 29 (13) 11 (5) 0.065 0.957
0.001 14 (6) 51 (23) b0.001 b0.001
0.001 24 (11) 39 (18) 0.176 b0.001
.790 18 (8) 18 (8) 0.723 0.869
0.001 22 (10) 53 (27) 0.006 b0.001
0.001 42 (19) 92 (41) b0.001 b0.001
0.001 29 (13) 29 (13) 0.816 b0.001
0.001 24 (11) 63 (28) 0.001 b0.001
0.001 24 (11) 41 (18) 0.226 0.005
0.001 106 [66–175] 676 [423–1108] b0.001 b0.001
0.001 73 [57–87] 50 [36–56] b0.001 b0.001
0.001 9.6 [4.6-24.2] 26.0 [20.0-45.7] 0.032 b0.001
0.001 138 ± 4 136 ± 6 0.029 b0.001
.627 23 [19–27] 37 [26–50] 0.005 0.032
0.001 93 ± 14 89 ± 24 0.281 b0.001
0.001 80 [76–89] 95 [80–100] 0.169 b0.001
0.001 63 ± 12 40 ± 18 b0.001 b0.001
0.001 0 (0) 57 (29) b0.001 b0.001
- 11 (5) - -
- 0 (0) - -
- 14 (6) - -
- 9 (4) - -
- 9 (4) - -
8 M. Berry et al. / IJC Metabolic & Endocrine 6 (2015) 5–12with 68±14 and 60±14, p b0.001, respectively andmore subjected to
diabetes and dyslipidemia. Signiﬁcant differences between control and
HF patients for medication, admission labs, echocardiography and ad-
mission vitals parameters were in agreement with their clinical status.
3.2. Differentially represented polypeptides determined by CE-MS and
identiﬁcation of a new candidate HF biomarker
We aimed at detecting putative biomarkers proﬁles that could be a
signature of HF using CE-MS analysis of urine samples from Toulouse
cohort as a ﬁrst step (Fig. 1A). Based on the urine proteome analysis of
the HF cases (AHF + CHF patients) and control subjects (CRF), we
have deﬁned a polypeptide set speciﬁc to HF (9 polypeptides with
AUC ≥ 0.923, p b 0.001 (after Benjamini Hochberg multiple testing
correction)) (Table S1). One polypeptide (x64054, mass 1878.792 Da;
electrophoresis time t = 20.722 s) seemed very interesting because it
showed an excellent discriminating power for HF with an AUC of
0.988, p = 1.39.10−5. Therefore, we could successfully identify it as
ISTMRLPDERGPLEHL, IPI:IPI00297284.1: the insulin like growth factor
binding protein 2 (IGFBP2). We ﬁrst checked by western blot analysis
the presence of IGFBP2 protein in human urine and blood. IGFBP2 was
more abundant in plasma that in urine (Fig. S1). ELISA analysis of
IGFBP2 urinary concentration revealed that the concentration was
505 ± 198 (n = 35) fold lower than in plasma (not shown). BecauseC R F N C D C H F A H F
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Fig. 2. IGFBP2 and BNP levels in plasma from the discovery-validation cohort. (A) IGFBP2 and B
(NCD), chronic heart failure (CHF) and acute decompensated heart failure (AHF) patients. * Si
IGFBP2 at 556 ng/ml determined with ROC curve analysis (B). (B) ROC curve analysis for CR
0.939) with a Youden index of 0.701 (CI 95%, 0.605- 0.775) with associated criterion N 106
0.900) with associated criterion N 556 ng/ml for IGFBP2. *Pairwise comparison of ROC curve wof this observation and the access to plasma samples from several co-
horts, we further analyzed IGFBP2 in plasma samples by ELISA.
3.3. IGFBP2 plasma concentration
We further analyzed IGFBP2 in plasma samples by ELISA in the local
validation cohort. Measurement of IGFBP2 in plasma revealed a signiﬁ-
cant increase in HF patients vs control subjects with 1051 (95% CI,
980–1161) and 120 ng/ml (95% CI, 98–134), respectively, p b 0.001
(Fig. 2A). BNP levels in HF cases were higher than in control subjects:
544 (95% CI, 385–677) and 43 (95% CI, 25–60) pg/ml, respectively,
p b 0.001 (Fig. 2A).
3.4. IGFBP2 correlationwith clinical characteristics and association with HF
diagnosis
Univariate analysis of correlation between IGFBP2 and BNP
with main characteristics parameters of the patients are reported in
Table 2. IGFBP2 and BNP levels were strongly correlated together
(Rho = 0.722; p b 0.001) and with diuretics medications with Rho =
0.620, p = 0.001 and Rho = 0.655, p b 0.001; respectively. BNP and
IGFBP2 were similarly correlated to LVEF (−0.653 and−0.669, respec-
tively). Univariate andmultivariate logistic regression analysis of associ-
ation of IGFBP2 with HF diagnosis shows that the ORs remain close toC R F N C D C H F A H F
1
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gniﬁcant difference; p b 0.05. Horizontal dashed line corresponds to optimal cut-point of
F+ NCD (n = 224) vs AHF + CHF (n = 112) patients. AUCs were 0.904 (CI 95%, 0.858-
pg/ml for BNP; 0.951 (CI 95%, 0.914-0.976) with Youden index of 0.837 (CI 95%, 0.756-
ere signiﬁcant between BNP and IGFBP2 with p = 0.031.
Table 2
Correlation of IGBP2 and BNPwith patient characteristics. Rho: Spearman rank correlation
coefﬁcient, n = 293; Rho N 0.5 moderate to high relationship in Bold.
IGFBP2 BNP
rho P rho P
Age, years 0.377 b0.001 0.374 b0.001
Sex, Female = 1 −0.005 0.942 0.024 0.720
BMI −0.232 b0.001 −0.126 0.070
Cardiovascular risk factors
Hypertensive 0.138 0.038 0.130 0.052
Diabetes 0.102 0.128 0.070 0.289
Dyslipidemia −0.120 0.071 −0.122 0.068
Obesity −0.233 b0.001 −0.138 0.038
Smoking −0.068 0.308 −0.043 0.525
Cardiovascular history
Coronaropathy artery disease 0.385 b0.001 0.348 b0.001
Medication
ACE inhibitor 0.254 b0.001 0.224 b0.001
ARAII −0.053 0.432 −0.020 0.762
Beta-blocker 0.335 b0.001 0.373 b0.001
Diuretic 0.620 0.001 0.655 b0.001
Vitamin K antagonist 0.191 0.004 0.349 b0.001
Antiplatelet agent 0.358 b0.001 0.278 b0.001
Statine 0.106 0.111 0.051 0.448
Admission labs
BNP, pg/ml 0.722 b0.001 _ _
Creatinine clairance −0.647 b0.001 −0.575 b0.001
C reactive protein 0.540 b0.001 0.530 b0.001
Na+ −0.300 b0.001 −0.286 b0.001
ALT 0.049 0.477 0.098 0.152
Mean Blood Pressure −0.406 b0.001 −0.331 b0.001
Heart rate 0.318 b0.001 0.346 b0.001
Echocardiography
LVEF −0.652 b0.001 −0.613 b0.001
1 10 100 1000 10000
100
1000
10000
BNP (pg/ml)
IG
FB
P2
(n
g/
m
l)
556
100 600
NCD
ADHF
Fig. 3. IGFBP2 and BNP levels in plasma from NCD and AHF patients from the discovery-
validation cohort. Levels of IGFBP2 and BNP for AHF and NCD. Horizontal line represents
the cut off value for IGFBP2 (556 ng/ml) and vertical lines delimit the poor diagnostic per-
formance zone for BNP between 100 pg/ml (the rule-out cut off for BNP) and 600 pg/ml
(the rule-in cut off for moderate heart failure).
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IGFBP2 AUC was 0.951 (95% CI, 0.914-0.976) and was measured as a
characteristic of IGFBP2 to discriminate between patients diagnosed
with heart failure (CHF+ AHF) and control patients i.e. with cardiovas-
cular risk factors or suffering of a non cardiac dyspnea (CRF + NCD)
with an optimal cut off value of 556 ng/ml. AUC measured for BNP on
the same patients was signiﬁcantly lower with 0.904 (95% CI, 0.858-
0.939), p b 0.031 (Fig. 2B). CHF patients were similarly discriminated
from CRF patients using IGFBP2 or BNP with an AUC of 0.988 (95% CI,
0.950-0.939) and 0.950 (95% CI, 0.897-0.980), p = 0.073, respectively.
IGFBP2 level was further tested for cardiac diagnostic power of pa-
tients admitted with dyspnea at intensive care cardiac unit (ICCU)
from Toulouse University Hospital (Table 1). Values of IGFBP2 and
BNP concentrations from these patients were presented to display the
global distribution of the patients (Fig. 3). ROC and NRI analyses were
performed to quantify the usefulness of IGFBP2 for the diagnosis of
AHF among these dyspneic patients presenting at the ICCU (Table 4).Table 3
Univariate and multivariate analysis of association of IGFBP2 with HF in the discovery-
validation cohort. Model 1, adjusted for demographics (age, gender); Model 2, adjusted
for above + cardiovascular risk factors (Hypertensive, diabetes, Dyslipidemia, Obesity,
smoking); Model 3, adjusted for age, gender and Medication (ACE inhibitor, ARAII, beta-
blocker, Diuretic, Vitamin K antagonist, statine); Model 4, adjusted for age, gender
and admission labs (BNP, Creatinine clairance, C reactive protein, Na, ALT); Model 5,
model 4 + admission vitals (MBP, HR). aOdds ratio of association between IGFBP2 per
100 ng/ml and HF.
ORa 95 %CI P
Model 1 1.96 1.66-2.32 b0.001
Model 2 2.13 1.74-2.60 b0.001
Model 3 2.12 1.61-2.80 b0.001
Model 4 1.90 1.54-2.35 b0.001
Model 5 1.95 1.57-2.42 b0.001Thus AUCs for IGFBP2were similar to that obtained for BNPwith no sig-
niﬁcant net reclassiﬁcation improvement. However, when considering
patients whose BNP concentration were in a poor diagnostic zone i.e.
100 to 600 pg/ml (Fig. 3) giving an AUC of 0.628 (95% CI, 0.459-
0.777), IGFBP2 showed a higher AUC value with 0.850 (95% CI, 0.699-
0.944) with a NRI of 0.488. It is noteworthy that a model combining
BNP + IGFBP2 gave the higher AUC and NRI (Table 4).
3.5. External validations of IGFBP2 as an AHF biomarker
Value of IGFBP2 measurement for HF diagnosis was investigated on
two external cohorts which included patients admitted to ED for dys-
pnea. A cohort of 40 patients recruited at the Paris Lariboisière Hospital
included 40patientswith 10NCD and 30AHF (Table 5). Indeed, a signif-
icant difference in IGFBP2 plasma concentrationwasmeasured between
NCD and AHF patients (Fig. 4). IGFBP2 levels provided an AUC of 0.943
(95% CI, 0.860-1.026) which gave a 87 % sensitivity in AHF and 90 %
speciﬁcity in NCD at the cut off value previously determined in the
discovery cohort from Toulouse University hospital, i.e. 556 ng/ml.
Finally, we tested the predicting value of IGFBP2 for HF diagnosis on
a cohort of 361AHF and 90NCDpatients recruited atMaastricht Univer-
sity Medical Center, Netherlands (Table 6). IGFBP2 levels were signiﬁ-
cantly increased in AHF vs NCD patients with 584 ng/ml (95 % CI,
538–614) vs 291 ng/ml (95% CI, 266–336), p b 0.0001 (Fig. 5), the OR
was 1.472 (95% CI, 1.293-1.646) p b 0.001, adjusted for age and gender.
ROC curve analysis of IGFBP2 and NTproBNP showed an AUC of 0.784
(95% CI, 0.744-0.820) for IGFBP2 and a signiﬁcantly higher AUC of
0.927 (95% CI, 0.900-0.949) for NT-proBNP, p b 0.0001. In this Dutch
cohort, the optimal cut off value for IGFBP2 was 440 ng/ml which gave
a sensibility of 71% (95% CI, 66–76) and a speciﬁcity of 75% (95% CI,
65–83). It is noteworthy that IGFBP2 levels and HF history were corre-
lated in this cohort (rho = 0.300; 95%CI, 0.228-0.367; p b 0.0001).
Indeed, multivariate analysis of association with HF history adjust-
ed for age and gender revealed that IGFBP2 was signiﬁcantly asso-
ciated with HF history 1.223 (95% CI, 1.132-1.321) OR, p b 0.001
whereas NT-proBNP was not signiﬁcantly with HF history 0.999
(95% CI, 0.982-1.017) p = 0.933 (Table S2).
3.6. Test of IGFBP2 in a rat model of ischemic HF
At day 20, i.e. 6 days after surgery induced ischemia, the animals had
a lowered ejection fraction (Fig. S2A) until day 70 when animals were
euthanatized and the organs collected. Analysis of the gene expression
levels in tissues showed that IGFBP2 mRNA levels were increased in
the ischemic animals atria compared with sham-operated (Fig. S2B).
At this time point, atria IGFBP2 mRNA levels from HF animals were
ten times higher vs ventricle and 4 times increased vs liver.
Table 4
ROC-AUC, area under the receiver operator characteristics curve; NRI, net reclassiﬁcation improvement betweenmodel with BNP andmodel with IGFBP2. Adjustment 1, adjusted for age
and gender; Adjustment 2, similar to Adjustment 1 but determined for patients with BNP plasma concentration between 100 and 600 pg/ml; Adjustment 3, adjusted for age and gender
based on BNP plasma concentration (reference predictor) or BNP + IGFBP2 (new predictor). aAUC are signiﬁcantly different from AUC = 0.5 with p b 0.001, *not signiﬁcantly different
for AUC = 0.5 with p = 0.174. bSigniﬁcance level of pairwise comparison of ROC curves. cContinuous NRI (NRI N 0).
ROC-AUCa (95% CI) P-valueb NRIc (95% CI) P-value
Models with BNP Models with IGFBP2
0.857 (0.770\0.921) 0.908 (0.830\0.958) 0.228 0.362 (−0.069\0.665) 0.048
Adjustment 1 0.848 (0.758\0.914) 0.906 (0.827\0.957) 0.164 0.351 (−0.143\0.670) 0.080
Adjustment 2 0.628 (0.459\0.777)* 0.850 (0.699\0.944) 0.020 0.488 (0.219\0.731) b0.001
Adjustment 3 0.848 (0.758\0.914) 0.931 (0.859\0.974) 0.008 0.574 (0.340\0.750) b0.001
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Plasma BNP or NT-proBNP levels are valuable tools to diagnose HF
[2]. Proteomics analysis led us to identify IGFBP2 as a potent biomarker
present in urine and in plasma for discriminating patients with HF. We
compared both IGFBP2 diagnostic value to the one of BNP and NT-pro-
BNP and the putative added value of IGFBP2. The diagnostic perfor-
mance of IGFBP2 has been evaluated in international multicentric
cohorts. Indeed, on the basis of c-statistic, we showed in the discovery
cohort that IGFBP2 had a better discriminating power than BNP for HF
patients. In patients with acute dyspnea from ICCU, IGFBP2 improved
the classiﬁcation of patients (NRI = 0.49) whose BNP concentrations
were in the poor prognosis zone of this biomarker i.e. ranged from 100
and 600 pg/ml. Value of IGFBP2 for diagnosis of AHF in patients present-
ing with dyspnea at ICCU were assessed in two external cohorts. Thus,
IGFBP2 showed a great capability to class with an AUC value higher
than 0.9 when tested with patients from the APHP Lariboisière HospitalTable 5
The Lariboisière University Hopital ED validation cohort demographic and clinical
characteristics.
NCD
(n = 10)
AHF
(n = 30)
P
Age, years 57 ± 10 73 ± 10 b0.001
Gender, Female, % (F/M) 30 (3/7) 23 (7/23) 0.689
Cardiovascular risk factors
Hypertensive, % (n) 30 (3) 63 (19) 0.140
Diabetes T2, % (n) 40 (4) 43 (13) 1.000
Dyslipidemia, % (n) 30 (3) 47 (14) 0.470
Obesity, % (n) 10 (1) 6 (2) 1.000
Cardiovascular history
Coronaropathy artery disease, % (n) 10 (1) 43 (13) 0.069
Valvular heart disease, % (n) 0 (0) 30 (9) 0.080
Clinical presentation
Acute heart failure _ 30 (9) _
Acutely decompensated heart
failure, % (n)
_ 60 (18) _
Pulmonary edema, % (n) _ 10 (3) _
Medication
ACE inhibitor or ARAII, % (n) 30 (3) 63 (19) 0.140
Beta-blocker, % (n) 0 (0) 57 (17) 0.010
Diuretic, % (n) 40 (4) 80 (24) 0.041
Vitamin K antagonist, % (n) 10 (1) 47 (14) 0.059
Antiplatelet agent, % (n) 30 (3) 60 (18) 0.148
Statine, % (n) 20 (2) 57 (17) 0.691
Admission labs
BNP, pmol/ml 14 [10–19] 1782 [1340–2773] b0.001
Creatinine, μmol/l 80 [65–100] 120 [98–142] 0.015
C reactive protein, mg/l 4.0 [0.0-14.5] 10 [0.7-19.5] 0.209
Na+, mM 139 ± 3 136 ± 7 0.043
Admission vitals
Mean Blood Pressure, mmHg 98 ± 13 93 ± 17 0.443
Heart rate, Bpm 104 ± 28 88 ± 26 0.107
Echocardiography
LVEF, % _ 35 [20–60] _Emergency Department (Paris, France) cohort that included NCD
patients with low BNP concentration i.e. below 20 pg/ml to exclude
dyspnea associated myocardial stress situation and patients with con-
ﬁrmed diagnosis of AHF. The second external validation cohort included
patients who presented with dyspnea as their main complaint either at
rest or during physical activity to the cardiology ED of the Maastricht
University Medical Center (MUMC, Maastricht, Netherlands). The dis-
criminating power of IGFBP2 was signiﬁcant with a 0.8 AUC value, but
lower than the 0.9 AUCmeasured with NT-proBNP which is the current
usual biomarker in use for HF diagnosis support in that ED.
IGFBP2 appeared as a new biomarker for the detection of HF that
brings additional information on the pathological status of the patient.
Indeed, IGFBP2 on the contrary to NT-proBNP was strongly associated
with HF history and IGFBP2 plasma concentration was signiﬁcantly
higher in stable chronic HF compared to noHF control cases thatmay in-
dicate theutility of IGFBP2 not only for the detection of overt HF, but also
in prognosis of HF patients. Furthermore, this apparent “memory of the
disease” raises questions on the underlying patholophysiological mech-
anisms. Based on our rat data, we propose that IGFBP2 synthesis could
be induced in the atria from HF patients. This IGFBP2 up-regulation
point out a potential role for Insulin-like growth factor (IGF)-binding
proteins (IGFBPs) in HF. It is well established that IGFBPs confer regula-
tion to insulin growth factor (IGF) bioactivity but can also have a direct
role [18–20]. Only one to 5 % of IGF1 is free in the blood stream, the
remaining IGF1 is tightly bound to IGFBPs with an afﬁnity that is greater
or equal to the one for its receptor [21].
IGFBP2 is mostly an IGF1 inhibitor. IGFBP2 is the second most abun-
dant IGFBP in human plasma. Our correlation data conﬁrmed that BNP
and IGFBP2 plasma levels are not dependant on sex but are positively
increased with age and negatively with the body mass index [22].NCD AHF
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Fig. 4. IGFBP2 in plasma from the external validation cohort from the Lariboisière Univer-
sity Hospital ED (Paris, France). *p b 0.01.
Table 6
The Maastricht University Medical Center ED validation cohort demographic and clinical
characteristics.
NCD
(n = 90)
AHF
(n = 361)
P
Age, years 73 [68–76] 78 [77–79] b0.001
Gender, Male, % (F/M) 58 (38/52) 53 (145/216) 0.814
Cardiovascular risk factors
Hypertensive, % 61 75 0.014
Diabetes, % 21 33 0.040
Dyslipedemia, % 55 58 0.905
Smoking, % 50 39 0.074
Cardiovascular history
Coronaropathy artery disease, % 46 50 0.527
Heart failure, % 33 45 0.061
Medication
ACE inhibitor, % 39 38 0.823
ARAII, % 25 22 0.714
Beta-blocker, % 54 61 0.244
Diuretic, % (n) 60 64 0.560
Anti thrombotic agent, % 67 78 0.035
Hypolipidemic agent, % 46 50 0.527
Admission labs
NT-proBNP, pmol/l 67 [42–104] 703 [610–831] b 0.001
IGFBP2 ng/ml 291 [266–336) 584 [538–614] b 0.001
Creatinine, μmol/l 101 [95–115] 116 [111–122] 0.001
C reactive protein, mg/l 9.0 [5.8-13.3] 15 [12–17] 0.007
Na+, mmol/l 139 [139–140] 139 [138–140] 0.699
ALT, U/ml 25 [21–29] 29 [26–31] 0.012
Admission vitals
BPS, mmHg 140 [135–145] 139 [131–140] 0.964
BPD, mmHg 70 [70–75] 75 [71–80] 0.020
Heart rate, Bpm 72 [70–78] 90 [86–94] b0.001
Echocardiography
LVEF, % 55 [45–60] 38 [35–40] b0.001
LVEF b 40%, % 9 36 b0.001
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opment [23]. IGF1 and its receptor are expressed in heart since the fœtal
stage and inducemyocardial hypertrophy. IGF1 also stimulatesmyocar-
dial protein production, including some with contractile functions such
as troponine and actin. IGF1 levels are correlated to the left ventricular
ejection fraction (LVEF) [24]. IGF1 is also involved in cardiomyocyte
survival and apoptosis [25,26]. Growth Hormone or IGF1 injection
have revealed a reduction of heart early remodeling, an improvement
of the systolic and diastolic function, and a contractility [27,28]. Recently,
the addition of the neutralising IGFBP2 antibody upon cell differentia-
tion led to an important myoblasts hypertrophy [29].100
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Fig. 5. IGFBP2 and NT-proBNP concentrations in plasma from the external validation
cohort from the cardiology ED of the Maastricht University Medical Center (Maastricht,
Holland). *** p b 0.001.This study allowed us to analyze the link between HF and plasma
IGFBP2 and the potential use of IGFBP2 as a new biomarker. We clearly
observed close to a 7-fold rise in IGFBP2 plasmatic concentration in HF
patients. IGFBP2 is mainly produced by the liver and the heart [30]
therefore is likely to be indicative of liver or heart function. These points
were evaluated in the ischemic rat model of HF which also revealed a
stronger IGFBP2 mRNA level in atria vs ventricle or liver. Above all,
IGFBP2 mRNA levels were signiﬁcantly increased in the atria from HF
animals. This observation raises the question of the putative role of
IGFBP2 in atria. One could speculate that IGFPB2 increased synthesis
could be involved in a protective mechanism against excessive remod-
eling in heart because reduction in vitro antibodies based neutralization
of IGFBP2 upon myoblasts differentiation led to hypertrophy [29]. In
addition, over expression of IGFBP2 led to a reduction in muscle mass
in the mouse [31]. However, despite solid backgrounds, this hypothesis
will have to be further tested in animals models of HF.
We observed a signiﬁcant negative correlation of the IGFBP2 level
with the LVEF value in patients. These observations tend to propose
the use of IGFBP2 as a potential follow-up biomarker that could be
used to estimate the stability and heart failure severity or prognosis.
Furthermore, since IGFBP2 levels were associated to HF history, this
observation support that IGFBP2 could be a prognosis biomarker that
has to be evaluated in further studies.
4.1. Study limitations
There are several limitations to the present study. The relatively
small number of patients in investigated cohorts decreased our ability
to generalize and and limited the statistical power of our analysis.
Thus, we observed different optimal cut-off value in the French and
the Maastrich cohorts (556 vs 440 ng/ml, respectively). This situation
could be explained by different collection, preparation and storage
scheme for the samples in the three centers. In favor of this hypothesis,
we observed a higher IGFBP2 plasma average concentration in the sam-
ples from AHF patients included from Paris and Toulouse University
hospital than in the Maastricht cohort. Moreover, NT-ProBNP assess-
ment was available in the emergency room whereas IGFBP2 was
measured from thawed samples. This situation could have lowered
the diagnostic value of IGFBP2 vs NT-Pro-BNP. These points should be
investigated in future studies.
5. Conclusion
The use of IGFBP2 as HF biomarker may improve HF diagnosis
especially in the BNP range of values indicative of mild to moderate
HF. Clearly, our data propose that IGFBP2 as a new biomarker that
could reveal the heart functional status. Studies with animal models
should be undertaken to understand the putative role of IGFBP2 in
heart.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcme.2014.11.003.
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